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Bloom syndrome (BS) is a genetic disorder associated with dwarfism, immunodeficiency, reduced fertility,
and an elevated risk of cancer. To investigate the mechanism of this disease, we isolated from human HeLa
extracts three complexes containing the helicase defective in BS, BLM. Interestingly, one of the complexes,
termed BRAFT, also contains five of the Fanconi anemia (FA) complementation group proteins (FA proteins).
FA resembles BS in genomic instability and cancer predisposition, but most of its gene products have no known
biochemical activity, and the molecular pathogenesis of the disease is poorly understood. BRAFT displays a
DNA-unwinding activity, which requires the presence of BLM because complexes isolated from BLM-deficient
cells lack such an activity. The complex also contains topoisomerase III and replication protein A, proteins
that are known to interact with BLM and could facilitate unwinding of DNA. We show that BLM complexes
isolated from an FA cell line have a lower molecular mass. Our study provides the first biochemical charac-
terization of a multiprotein FA complex and suggests a connection between the BLM and FA pathways of
genomic maintenance. The findings that FA proteins are part of a DNA-unwinding complex imply that FA
proteins may participate in DNA repair.
Humans and mice with mutations in either one or both cop-
ies of the BLM gene have a higher risk of developing cancer (8,
13, 14, 30). BLM belongs to the RecQ family of DNA helicases
(8) and possesses a DNA-unwinding activity for several types
of DNA substrates (3, 25, 26, 33, 39). Interestingly, two other
members of the RecQ family are mutated in the Werner (51)
and Rothmund-Thomson (27) syndromes, which feature both
premature aging and genomic instability and predisposition to
cancer (23, 32). Mutation in RecQ helicases in other species
results in similar genome instability phenotypes. The fact that
defects in three of five known human RecQ helicases cause
genome instability diseases suggests that this family of proteins
plays key roles in maintaining the integrity of the genome.
Because the phenotypes of the three diseases are different,
these helicases presumably function in distinct complexes and
pathways.
In the case of BLM, several of its interacting proteins have
been reported. These include topoisomerase III (opo III)
(19, 22, 47), an enzyme that can stimulate helicase activity by
relieving the torsional stress produced during unwinding of
DNA; replication protein A (RPA) (2), a DNA-binding pro-
tein that plays essential roles in DNA replication and nucleo-
tide excision repair; MLH1 (29, 38), a protein involved in
mismatch repair and defective in colon cancer (1, 36); and
p53, a tumor suppressor mutated in many cancers (45). In
addition, BLM has been found in the BRCA1-associated ge-
nome surveillance complex, BASC (46). However, the endog-
enous BLM complexes have not been purified by unbiased
biochemical approaches. Consequently, basic questions re-
garding BLM remain unanswered, including the number and
composition of BLM complexes that exist in a given cell type.
Fanconi anemia (FA) is a genetic disease characterized by
congenital defects, bone marrow failure, and cancer suscepti-
bility (21). As with Bloom syndrome (BS), the cells derived
from FA patients exhibit genomic instability. Eight comple-
mentation groups have been described for this disease, and
their corresponding genes have been identified (18, 21, 41).
Five FA proteins (A, C, E, F, and G) have been suggested to
interact with each other to form a multiprotein nuclear com-
plex, the “core complex” (7, 11, 31). Recent evidence suggests
that FA proteins function in a DNA damage response pathway
involving breast cancer susceptibility genes 1 and 2 (BRCA1
and BRCA2, respectively). For example, following DNA
damage induced by mitomycin C (MMC), an FA protein,
FANCD2, becomes monoubiquitinated and redistributes into
nuclear foci, where it colocalizes with BRCA1 (12). In addi-
tion, another FA protein, FANCD1, has been identified as
BRCA2 (18). BRCA2 can regulate the activity of Rad51 (6)
and may participate in homologous repair of DNA damages as
a DNA-binding protein (42, 50). However, the mechanism of
this disease remains unclear because most FA proteins lack
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recognizable structure motifs, and none of them has been
associated with any biochemical activity.
We have previously purified several ATP-dependent chro-
matin-remodeling complexes (44, 48, 49). They all contain an
SWI2/SNF2-like ATPase or helicase. Often, one ATPase is
present in several distinct complexes, each of which has a
unique function. Thus, to understand the function of a partic-
ular ATPase, each complex containing the protein must be
purified and analyzed. Because of the importance of RecQ
helicases in maintaining genome stability, we sought to system-
atically purify each endogenous RecQ helicase complex and
study their functions. We report here the purification and
analysis of proteins in three distinct BLM-associated multipro-
tein complexes from human HeLa cells. Interestingly, one of
these complexes includes five FA core complex proteins, which
suggests a functional connection between the pathways dis-
turbed in these genomic instability syndromes.
MATERIALS AND METHODS
Cell culture. Three types of Epstein-Barr virus (EBV)-immortalized lympho-
blasts—i.e., wild-type (ManEBV), FA-A (VU388), and BLM (2036) cell lines—
were maintained in RPMI medium (Life Technology) supplemented with 10%
heat-inactivated fetal calf serum and grown in a humidified 5% carbon dioxide
(CO2)-containing atmosphere at 37°C. HeLa S3 cells were obtained from the
National Cell Culture Center. For MMC-treated HeLa cells, the cells were
treated with 40 ng of MMC/ml for 24 h.
Antibodies. Monoclonal and polyclonal antibodies to FANCA, FANCF,
FANCG, FANCC, and FANCE have been described elsewhere (7, 15, 35, 43).
The rabbit BLM polyclonal antibody (69D) was raised against a chimeric protein
containing a region of BLM (amino acids 230 to 330) fused to maltose-binding
protein. This antibody was affinity purified and used for immunoaffinity purifi-
cation of BRAFT. A goat polyclonal antibody (C-18) to BLM (Santa Cruz
Biotechnology) was used for immunoblotting analysis. Antibodies to RPA34
(AB1) and RPA70 (AB2) were from Neomarker. Antibody to RPA14 was from
Genetex. Monoclonal antibody to BRCA1(AB1) and polyclonal antibody to
MLH1(AB2) were from Oncogene. Antibodies to human Topo III were kind
gifts of L. Guarente. A polyclonal FANCD2 antibody was generated by immu-
nizing rabbit with recombinant protein containing maltose-binding protein and
an N-terminal region of FANCD2 (Z. Yan, unpublished results).
Immunoprecipitation. BLM complexes were isolated from HeLa S3 nuclear
extract by using an immunoprecipitation protocol described previously (C. S. Lee
et al., unpublished data). Briefly, 1 ml (8 mg/ml) of nuclear extract was diluted 10
times with IP buffer (20 mM HEPES [pH 7.9], 200 mM NaCl, 1 mM dithiothre-
itol [DTT], 0.2 mM phenylmethylsulfonyl fluoride [PMSF], 10% glycerol) and
incubated with 5 g of affinity-purified rabbit polyclonal antibody (69D) in the
presence of 100 l of protein A-beads (Amersham Pharmacia) for at least 12 h.
The immunoprecipitate was washed four times with the IP buffer. The complex
on the beads was either used directly for the helicase assay or was eluted from the
beads by using 100 mM glycine-HCl buffer (pH 2.5). The eluted complex was
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and immunoblotting analysis. Less than 10% of the input was loaded as
controls for immunoblotting. For mass spectrometric analysis, the proteins were
visualized by Coomassie blue staining, excised from the gel, and digested with
trypsin. The peptides obtained were analyzed by matrix-assisted laser desorption
ionization–time of flight and/or liquid chromatography-mass spectrometry anal-
yses. The data are not shown but are available upon request. All other coimmu-
noprecipitations were carried out as described above or in the legends.
Nuclear extract fractionation. The HeLa S3 nuclear extract (16 mg) was
directly applied to a Superose-6 column (HR 16/50; Amersham) equilibrated
with the column running buffer containing 20 mM HEPES (pH 7.9), 200 mM
NaCl, 1 mM DTT, 0.1 mM PMSF, and 10% glycerol. Fractions were collected
(1.5 ml each) and analyzed by SDS–8% PAGE and immunoblotting. The peak
fraction was directly loaded onto antibody beads for immunoprecipitation as
described above. For human lymphoblastoid cells, nuclear extracts were diluted
twofold with buffer containing 20 mM HEPES (pH 7.9)–1 mM DTT–0.1 mM
PMSF before they were loaded onto an HR 10/30 Superose-6 column (Amer-
sham). Fractions were then collected (0.5 ml) and analyzed by immunoblotting.
DNA helicase assay. A 5-end-labeled oligonucleotide was annealed to an
M13mp18 single-stranded DNA (New England Biolabs) to obtain a partial
duplex DNA with a 3 overhang region. Helicase assay reaction mixtures (40 l)
contained 200 cpm of partial duplex DNA substrate, 50 mM Tris-HCl (pH 7.5),
5 mM MgCl2, 2 mM ATP, 100 g of bovine serum albumin/ml, 50 mM NaCl, and
the indicated amounts of complexes isolated by using either BLM or FANCA
antibody. Reactions were carried out at 37°C for 30 min. The reactions were
stopped by the addition of 10 l of 6 high-density gel loading dye (Novex)
containing 50 mM EDTA and 0.8% SDS. The products of helicase reactions
were resolved on 10% nondenaturing polyacrylamide gel and visualized by au-
toradiography.
RESULTS
BLM-associated polypeptides include Topo III, RPA,
MLH1, and five FA proteins. We isolated the endogenous
BLM-associated complexes from human HeLa nuclear extract
by direct immunoprecipitation with a BLM-specific antibody.
BLM coimmunoprecipitated with about 10 major polypeptides
(abbreviated as BLAPs for BLM-associated polypeptides)
(Fig. 1A). These polypeptides were not immunoprecipitated
with preimmune serum from the same rabbit, suggesting that
they could represent components of BLM-associated com-
plexes. The 170-kDa polypeptide was identified as BLM by
both mass spectrometry and immunoblotting analysis (Fig. 1A
and B). Five other BLAPs were similarly identified as Topo
III, three subunits of RPA, and MLH1. All of these proteins
have been reported to interact with BLM (2, 19, 29, 38, 47).
The fact that three known BLM-interacting proteins have been
recovered validates the isolation protocol and suggests that the
polypeptides obtained could all be components of one or sev-
eral BLM-associated complexes.
BLAPs isolated in the present study do not contain BRCA1
and eight of the other known components of the previously
described BLM-containing complex, BASC, which was also
isolated from HeLa cells (Fig. 1C and data not shown) (46).
MLH1 is the single component present in both the BASC and
BLAPs. However, data below show that the BLM-MLH1 com-
plex described here contains other components not reported to
occur in the BASC. In addition, our complex is 600 kDa,
which is considerably smaller than the reported mass of the
BASC (2 MDa). Therefore, the BLM complexes reported
here are different from the BASC.
The BLAPs described here also do not contain p53 (data not
shown), which has been reported to interact with BLM (45).
However, the present study used HeLa cells in which p53 was
inactivated by association with HPV-E6 oncoprotein. Future
studies with cell lines that contain wild-type p53 will be needed
to isolate the BLM-p53 complex.
One of the remaining BLAPs was identified as an FA pro-
tein, FANCA, by mass spectrometry and immunoblotting (Fig.
1A and B). Five FA proteins (referred to as core complex
FA proteins)—FANCA, FANCC, FANCE, FANCF, and
FANCG—have previously been suggested to form a nuclear
complex (7, 11, 31). Thus, the identification of FANCA as a
BLAP hinted that the other four FA proteins could also be
present in BLM complexes. This was confirmed by immuno-
blotting showing that all five FA proteins—FANCG, FANCC,
FANCE, FANCF, and FANCA—all associate with BLM (Fig.
2B).
FANCA-associated polypeptides include five FA proteins,
together with BLM, Topo III, and RPA. Although FANCA
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has been suggested to form a nuclear complex with four other
FA proteins, this complex has not been purified and charac-
terized. We immunoprecipitated FANCA-associated polypep-
tides (abbreviated as FAAPs for FANCA-associated poly-
peptides) by immunoprecipitation and found by both mass
spectrometry and immunoblotting that they include all five
core complex FA proteins (Fig. 2A and B). The finding that the
FAAPs include all five FA proteins confirms and strengthens
the earlier evidence for a nuclear FA complex that may play a
critical role in FA. Speculatively, the remaining FAAPs may be
components of the same FA complex.
Importantly, three of the remaining FAAPs were identified
as BLM, Topo III, and RPA70 by both mass spectrometry
(Fig. 2A) and immunoblotting (Fig. 2D). Because BLM, core
complex FA proteins, Topo III, and RPA can be immuno-
precipitated by both BLM and FANCA antibodies, they ap-
pear to be components of the same complex.
FANCA has been reported to associate with the human
ATP-dependent chromatin-remodeling complex, SWI/SNF
(34). However, we failed to detect any human SWI/SNF com-
ponents in the FAAPs (data not shown).
RPA and Topo III are components of the same complex
containing BLM and core complex FA proteins. RPA and
Topo III have been shown to interact independently with
BLM (2, 19, 47) but have not previously been found together
in a single complex. RPA and Topo III-associated polypep-
tides were isolated by immunoprecitation and were found to
exhibit similar mobilities on an SDS gel that not only resemble
one another but also the mobilities of BLAPs and FAAPs (Fig.
2C). Immunoblotting showed that the two groups of proteins
include not only RPA and Topo III but also BLM, FANCA,
and FANCG (Fig. 2D). Because these proteins can be coim-
munoprecipitated by each respective antibody, they must be
components of the same complex. We termed this complex
BRAFT (for BLM, RPA, FA, and Topo III).
The relative amounts of the BRAFT components isolated by
different antibodies were compared based on their intensities
on a silver-stained gel and their immunoblotting signals (Fig.
2C and D). The amounts of FANCA and several of its asso-
ciated polypeptides (FAAP100, FANCG, and FAAP43) iso-
lated with FANCA antibody are greater than those isolated by
BLM and other antibodies, implying that significant amounts
of core FA proteins may be present in complexes other than
BRAFT (see also Fig. 4A). Likewise, the amounts of three
RPA components immunoprecipitated with an RPA antibody
are also significantly greater than the other subunits of BRAFT
(Fig. 2C), suggesting that only a small percentage of RPA
associates with BRAFT.
FIG. 1. Novel BS complexes contain Topo III, RPA, and MLH1. (A) A silver-stained gel showing the novel BS complexes isolated by
immunoprecipitation with a BLM antibody from a HeLa nuclear extract. The polypeptides identified by mass spectrometry analysis are indicated
by an asterisk. The polypeptides that remain to be identified (termed BLAPs) are also marked. The presence of immunoglobulins (immunoglobulin
G [IgG] H and IgG L) are indicated. A control immunoprecipitation was included with the preimmune serum of the same rabbit. (B and C)
Autoradiographs illustrating the immunoblotting analysis of load, flowthrough (FT), and eluted (Elute) fractions from the immunoaffnity
purification by the BLM antibody. The antibodies utilized for immunoblotting are shown.
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The association between BLM and the core complex FA
proteins is specific. To rule out the possibility that BRAFT
components may be isolated through nonspecific interactions
with protein A-beads or antibodies, a control immunoprecipi-
tation was performed with matched preimmune sera for both
BLM and FANCA antisera. None of the BRAFT components
was isolated, thus ruling out this possibility (Fig. 2D). To ex-
clude another possibility that BLM and FANCA antibodies
may cross-react, immunoprecipitation was done with nuclear
extracts from human lymphoblastoid cell lines lacking either
FANCA or BLM. These cell lines were derived from either FA
or BS patients that carry mutated FANCA or BLM genes,
respectively. It was noted that, in FANCA-deficient cells,
FANCG was also absent (Fig. 3A), a finding consistent with
earlier observations that these two proteins stabilize each other
(10). BLM and FANCA antibodies immunoprecipitated each
other and their associated proteins only from wild-type cells
and not from their respective mutant cells, indicating that the
antibodies do not cross-react (Fig. 3B). To eliminate a further
possibility that BLM may associate with FA proteins through
DNA, immunoprecipitation was performed in the presence of
ethidium bromide (EtBr), a DNA-intercalating drug that can
prevent proteins from binding to DNA and has been fre-
quently used to identify DNA-independent protein associa-
tions (28). Both FANCA and FANCG were immunoprecipi-
tated by BLM antibody in the presence of EtBr, and their
levels are comparable to those immunoisolated in the absence
of EtBr (Fig. 3C), indicating that the association between BLM
and FA proteins is not through DNA.
A proportion of BLM and core complex FA proteins can
form independent complexes. The amounts of BLM and Topo
III immunoisolated by BLM antibody from FANCA-deficient
cells are similar to those obtained from wild-type cells (Fig.
3B), indicating that the interaction between BLM and Topo
III does not require FA proteins. The result also showed that
BLM and Topo III could form complexes that lack FA pro-
teins, a finding consistent with our data below (Fig. 4). Like-
wise, the amounts of FANCA and FANCG immunoprecipi-
tated by FANCA antibody from BLM-deficient cells are
similar to those obtained from wild-type cells (Fig. 3B), indi-
cating that the association between the core complex FA pro-
teins is not dependent on BLM. Moreover, our results suggest
that core complex FA proteins may form their own complexes
without BLM. Interestingly, Topo III was immuoprecipitated
by FANCA antibody from wild-type cells but not from BLM-
deficient cells, suggesting that the FA proteins may associate
with Topo III and other BRAFT subunits through BLM.
Only one of the three BLM complexes contains FA proteins.
We further characterized BLM complexes by fractionating
HeLa nuclear extract through a Superose-6 sizing column.
BLM fractionated in three separate complexes, termed BLM
complexes I, II, and III, corresponding to masses of ca. 1.5 to
FIG. 2. Five FA complementation group proteins are present in one complex with BLM, Topo III, and RPA. (A) A silver-stained gel showing
the polypeptides associated with endogenous FANCA (FAAPs) in comparison with BRAFT. Note that FANCA antibody was cross-linked to
protein A-beads prior to immunoprecipitaion. The polypeptides identified by mass spectrometry analysis are marked with an asterisk. (B) Im-
munoblotting data showing the presence of multiple FA proteins in polypeptides isolated by using FANCA and BLM antibodies. As a positive
control for FANCC and FANCF, whole-cell lysate from 293 cells transiently transfected with vectors expressing either epitope-tagged FANCC-HA
or FANCF-Flag was used. HeLa nuclear extract was used as a positive control for BLM, FANCA, and FANCG. (C and D) A silver-stained gel
(C) and Western blotting analysis (D) of the polypeptides associated with endogenous BLM, RPA70, Topo III, and FANCA. The antibodies used
for each immunoprecipitation are indicated on top of the figure. Mock immunoprecipitation with preimmune sera was used as the control. All
immunoprecipitations were done with HeLa nuclear extract.
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2.0 MDa, 1 MDa, and 600 kDa, respectively (Fig. 4A). No
detectable BLM fractionated as the free protein at its calcu-
lated molecular mass (160 kDa), suggesting that essentially all
BLM exists in high-molecular-mass complexes in cells. Each
BLM complex was immunoprecipitated from its corresponding
column fractions and displayed differential subunit composi-
tion by SDS-PAGE analysis (Fig. 4B). Only the 1.5- to 2-MDa
complex contains the FANCA polypeptide (lane 2). The same
complex also includes Topo III, RPA, and other FA proteins
(Fig. 4C), indicating that this complex is BRAFT. In compar-
ison, BLM complexes II and III lack FANCA by silver-staining
analysis (Fig. 4B), which was confirmed by immunoblotting
analysis showing that they lack both FANCA and FANCG
(data not shown; but see Fig. 4D). In complex I, the amounts
of FANCA and BLM are more stoichiometric than those ob-
tained by direct immunoprecipitation from nuclear extract
(Fig. 4B, compare the relative intensities of FANCA and BLM
bands in lanes 2 and 1). This is consistent with the greater
purity of the BRAFT complex immunoisolated after Super-
ose-6 fractionation, which has separated away the BLM com-
plexes (II and III) that lack FA proteins. The 1-MDa BLM
complex II contains Topo III and RPA but no FA proteins
(Fig. 4B). Because the only difference between complexes I
and II appears to be the FA proteins, it is possible that complex
II is a subcomplex of complex I. The 600-kDa BLM complex
III contains Topo III and MLH1 but no RPA or FA proteins.
Only a subset of FANCA associates with BLM. Superose-6
fractionation also revealed that FANCA is in three different
complexes corresponding to molecular masses of ca. 1.5 to 2.0
MDa, 900 kDa, and 500 kDa (Fig. 4A). Only the first one
comigrates with BRAFT in a 1.5- to 2-MDa complex. Immu-
noprecipitation from the 1.5- to 2-MDa fraction by using
FANCA antibody yielded BLM and other BRAFT compo-
nents, a finding consistent with the results presented above
indicating that BRAFT is a 1.5- to 2-MDa complex (data not
shown). In addition, substantial amounts of BLM and FANCA
overlap in the 900- and 500-kDa fractions. However, the pos-
sibility that these two proteins might also participate in smaller
complexes was ruled out because BLM coimmunoprecipitated
with FANCA only from the 1.5- to 2-MDa fraction but not
from the two smaller fractions (Fig. 4D). Another FA core
complex protein, FANCG, displayed a fractionation profile
almost identical to that of FANCA by Superose-6 analysis
(data not shown). We infer that these core complex FA pro-
teins could occur in at least two complexes without BLM.
BLM complexes from a FANCA-deficient cell line have
lower molecular masses. We compared the molecular masses
of BLM complexes from a FANCA-deficient cell line to those
from a normal lymphoblastoid cell line by Superose-6 analysis.
If FA proteins are required components of the BLM complex,
the complexes isolated from a FANCA-deficient cell line
should be smaller. This expectation was confirmed, since the
majority of BLM from a FANCA-deficient cell line fraction-
ated as a complex of 1 MDa (Fig. 5), corresponding to the
BLM complex II of HeLa cells that lacks FA proteins. In
contrast, most BLM from wild-type cells fractionated as the
1.5- to 2-MDa BRAFT complex. We infer that in the absence
of FANCA, the BRAFT complex loses its FA components,
becoming the smaller 1-MDa BLM complex.
It was noted that by Superose-6 analysis, the peak corre-
sponding to BLM complex II of the normal lymphoblastoid cell
line (Fig. 5, fractions 21 to 22) is not that obvious compared to
that of HeLa cells (Fig. 4A). It is possible that the level of BLM
complex II, which lacks FA proteins, is variable between cell
lines.
BLM- and FANCA-associated complexes have a DNA-un-
winding activity that requires the presence of BLM. BLM
complexes immunoisolated from HeLa or a normal lympho-
FIG. 3. BLM and FANCA antibodies immunoprecipitate their associated complexes from wild-type but not their respective mutant cell lines.
(A) Autoradiographs showing immunoblotting analysis of nuclear extracts prepared from wild-type (ManEBV), BLM/ (2036), and FANCA/
(VU388) human lymphoblastoid cell lines. After SDS-PAGE and Western transfer, the membrane was cut into two parts. The part corresponding
to a molecular mass of	120 kDa was probed by using a mixture of BLM and FANCA antibodies (top panel). The other part was analyzed by using
a mixture of Topo III and FANCG antibodies (bottom panel). Note that FANCG was not detected in the FANCA-deficient cells. (B) Immu-
noblotting analysis of the polypeptides isolated by either BLM or FANCA antibodies from the three lymphoblastoid cell lines. The antibodies used
for immunoprecipitation are indicated on the top, whereas those used for immunoblotting are listed on the right. (C) Immunoblotting analysis
showing that the association between BLM and FA proteins remains intact in the presence of EtBr, a DNA-intercalating drug that can disassociate
proteins from DNA. In this experiment, 50 g of EtBr/ml was included in the immunoprecipitation mixture.
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blastoid cell line displayed a helicase activity that unwinds
duplex DNA (Fig. 6A and B; see Fig. 3 for analyses of immu-
noprecipitates from various lymphoblastoid cell lines), a find-
ing consistent with previous results that recombinant BLM is a
DNA helicase (25). The observed activity should be derived
from BLM, but not a contaminant, because a mock immuno-
precipitation from a BLM-deficient cell line failed to isolate
this activity. BLM immunoprecipitate from a FANCA-defi-
cient cell line has a helicase activity indistinguishable from that
isolated from the control cell line, suggesting that FA proteins
do not affect the helicase activity of BLM, at least with this
DNA substrate.
Importantly, complexes isolated with the FANCA antibody
from HeLa or a normal lymphoblastoid cell line displayed
similar helicase activities (Fig. 6C and D), whereas mock im-
FIG. 4. The BRAFT complex containing BLM and FA proteins is one of the three BLM complexes in the nuclear extract. (A) Immunoblotting
analysis of different fractions from Superose-6 fractionation of HeLa nuclear extract. The fraction numbers are indicated on the top. The fractions
corresponding to proteins of known molecular mass are denoted below the figure in kilodaltons. The void volume of the column is marked as
“void.” The fractions in which BLM peaked are marked at the top as BCI, BCII, and BCIII (for BLM complexes I to III). The letters a, b, and
c indicate the overlapping peak fractions between BLM and FANCA. A false-positive band derived from antibody cross-reactivity (which is also
present in fractions from FANCA-deficient cells) is indicated by an asterisk. (B) Silver-stained gel showing the composition of three BLM
complexes, which were immunoprecipitated with a BLM antibody (69D) from the three BLM peak fractions after Superose-6 fractionation (see
panel A). The immunoprecipitations were carried out directly from each of the corresponding fractions (i.e., fractions 24, 30, and 36) without
further dilution. BLM immunoprecipitate from total nuclear extract (NE) is shown for comparison. (C) Western blotting analysis showing the
presence of multiple FANC proteins in the BRAFT complex. Fraction 24 of Superose-6, which corresponds to the 1.5- to 2-MDa fraction, was used
as a positive control. (D) Immunoblotting of BLM immunoprecipitates (IPs) from three different Superose-6 fractions—a, b, and c—in which
significant amounts of BLM and FANCA overlap. Notably, BLM coimmunoprecipitates with FANCA and FANCG only from fraction A, which
corresponds to a molecular mass of 1.5 to 2 MDa (BRAFT).
FIG. 5. The BLM complexes are present in smaller forms in an FA
cell line. Immunoblotting analysis of different fractions from Super-
ose-6 fractionation of the wild-type (ManEBV) and FANCA-deficient
(VU388) lymphoblastoid cell lines. Notably, BLM peaks at fraction 21
in the FANCA-deficient cells, corresponding to a complex of ca. 1
MDa. This is smaller than the BLM from the wild-type cells, which peaks
between fractions of 17 and 18, corresponding to a complex of 1.5 to
2 MDa (BRAFT). It was noted that BCII in this analysis is not that
obvious, which may be due to its different levels in different cell lines.
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munoprecipitation from a FANCA-deficient cell line yielded
no activity (Fig. 6D). Thus, this activity is apparently not due to
a contaminant. FANCA immunoprecipitate from BLM-defi-
cient cells also lacked helicase activity (Fig. 6D), suggesting
that BLM is required for the observed activity. All of these
data are consistent with a notion that BLM and FA proteins
are components of one nuclear complex that can unwind DNA
through the BLM helicase.
FA proteins and BLM do not function in a signaling path-
way through monoubiquitination. Recent evidence suggests
that core complex FA proteins control the activation of
FANCD2 by monoubiquitination in a DNA damage response
pathway (12). The findings that BLM and core complex FA
proteins are present in the same complex prompted us to
explore the possibility that BLM may be involved in the same
pathway. However, the level of FANCD2 monoubiquitination
in BLM-deficient cells was found to be indistinguishable from
that in normal lymphoblast cells (Fig. 7A). As a monoubiquiti-
nation was completely absent in the FANCA-deficient cells.
The results suggest that BLM does not function upstream of
the core complex FA proteins in this pathway. In addition,
under DNA damage conditions in which a high level of
FANCD2 monoubiquitination was induced, no ubiquitination
was detected for BLM, Topo III, and RPA (Fig. 7B), arguing
against these proteins being downstream ubiquitination targets
of the FA complex. Together, these data suggest that FA
proteins and BLM do not act in a linear signaling pathway
through monoubiquitination.
DISCUSSION
RecQ helicases play key roles in maintaining genome stabil-
ity and preventing early onset of aging. However, their exact
mechanisms of action remain unclear. One reason is that the
functional units of these helicases in vivo—the endogenous
complexes containing them—have not been purified and stud-
ied. We report here three human complexes containing the
BLM helicase involved in BS and demonstrate that they have
distinct subunit compositions. One complex contains five FA
proteins, whereas another contains MLH1, a protein involved
FIG. 6. Complexes isolated by BLM and FANCA antibodies possess a DNA-unwinding activity that requires the presence of BLM. (A-D)
Autoradiographs showing the results of a helicase assay for complexes isolated by antibodies to BLM or FANCA. The partial DNA duplex
substrate and the displaced single-strand oligonucleotide (Oligo) are illustrated on the left of the figure. Also analyzed were fractions isolated by
control (mock) immunoprecipitation (Mock IP) with preimmune serum of the BLM antibody or normal rabbit IgG for the FANCA antibody. The
cell lines and antibodies used for immunoprecipitations are indicated on the top. For complexes isolated from HeLa cells, 0 to 200 ng of the
BLM-associated complexes or 0 to 500 ng of FANCA-associated complexes are used for the helicase assay (A and C). For lymphoblastoid cells,
0 to 50 ng of BLM-associated complexes and 0 to 100 ng of FANCA-associated complexes were analyzed (B and D). Maximum amounts of
complexes were assayed in those isolated from BLM-deficient cells. To ensure that comparable amounts of BLM were present in complexes
isolated from wild-type (WT) and FANCA-deficient cells, each immunoprecipitate was analyzed by immunoblotting with a BLM antibody, and the
results are shown as a small figure at the bottom of panel B.
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in mismatch repair and mutated in colon cancer. Identification
of these distinct complexes permits further biochemical char-
acterization of their roles in cellular pathways and in disease
etiology.
The most important finding of the present study is the ob-
servation that five FA proteins are part of a BLM complex that
possesses a DNA-unwinding activity. To our knowledge, this is
the first biochemical activity for a complex containing the en-
dogenous FA proteins. Our data imply that these FA proteins
may have a function in DNA repair as part of this BLM-
dependent DNA-unwinding complex. Thus far, the molecular
function of the FA core complex proteins remains unknown.
They have been proposed to function in at least two distinct
pathways: DNA repair and detoxification of reactive oxygen
species (4, 5). More-recent evidence suggests that these FA
proteins control the activation of FANCD2 by monoubiquiti-
nation, a step required for DNA-damage-dependent colocal-
ization with BRCA1 (12). Our Superose-6 analysis shows that
FANCA is present in at least three nuclear complexes, only
one of which contains BLM (Fig. 4). It will be important to
determine the composition of the other two FANCA-contain-
ing complexes, as well as their function.
Although BS and FA cells have strikingly different pheno-
types, with elevated sister chromatid exchanges in the former
and cross-linker-induced quadriradials in the latter, a connec-
tion between the two diseases may be inferred from several
lines of earlier evidence. First, both conditions feature genomic
instability, predisposition to cancer, and reduced fertility. Sec-
ond, the type of spontaneous chromosomal instability in FA
was noted to be similar to that of BS (21), showing mainly
chromatid breaks and interchanges. This is in contrast to other
caretaker gene disorders that favor deletions, rearrangements,
and variable chromosomal numbers. The similarity also ex-
tends to the chromosomal aberration observed in BRCA2-
deficient cells, which was found to be similar to that in both BS
and FA cells (37), long before BRCA2 was identified as an FA
gene itself (18). Third, some FA cells have elevated homolo-
gous recombination activity (40) and a higher frequency of
sister chromatid exchanges (9, 16, 24), which are reminiscent of
BS cells. Fourth, certain BS cells exhibit increased sensitivity to
MMC (17, 20), a hallmark of FA cells.
Our data link BS and FA by showing that BLM and five FA
proteins are components of a single complex. The findings that
this complex includes at least three DNA-binding and remod-
eling proteins (BLM helicase, Topo III, and RPA) and pos-
sesses a DNA-unwinding activity suggest that it could partici-
pate in the removal of aberrant DNA structures formed during
dynamic processes such as DNA replication and repair. In
accord with this notion, BLM helicase is capable of unwinding
several types of DNA structures (3, 26, 33, 39). Topo III
could facilitate unwinding by relieving the torsional stress gen-
erated by the helicase. RPA may play one or both roles in this
process: it may participate in recognition of the DNA damage,
just as it does for nucleotide excision repair, or it may facilitate
the unwinding reaction by stabilizing single-stranded DNA
generated by the BLM helicase. The single-stranded DNA thus
generated could then serve as a critical intermediate in recom-
bination or repair. Malfunction of proteins in this complex
could result in the accumulation of aberrant DNA structures
that lead to chromosomal aberrations observed in these dis-
eases.
An important unanswered question is how BLM and FA
proteins function together in the BRAFT complex. Currently,
there is no biochemical activity described for the core complex
FA proteins, which makes it difficult to establish a functional
connection between BLM and FA proteins. Our ubiquitination
analyses suggest that these proteins do not function in a linear
signaling pathway through monoubiquitination (Fig. 7). How-
ever, our ongoing work has suggested a new possibility: that
core complex FA proteins, or their associated FAAPs, may
possess DNA-modifying activities that are complementary to
those present in BLM, Topo III, and RPA during unwinding
of the damaged DNA. In other words, FA proteins and BLM
may not regulate each other’s activity but instead may modify
DNA structures in concert in sequential steps during the DNA
repair process. Indeed, we found that one of the uncharacter-
ized FAAPs contains a DNA endonuclease domain highly ho-
mologous to that of a protein known to be involved in DNA
damage repair (unpublished data). Speculatively, FA proteins,
through this FAAP, may provide a DNA-cutting activity nec-
essary for the subsequent unwinding step catalyzed by the
BLM helicase. Future experiments will be needed to analyze
whether BRAFT has multiple DNA-modifying activities that
cooperate to unwind the damaged DNA.
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